C. difficile and S.aureus bacteraemia surveillance quarterly reports

Quarterly reports provide epidemiological data on�C. difficile and S. aureus�in Northern Ireland. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.Click here to see the latest reports

Sexually Transmitted Infection surveillance in Northern Ireland 2014

Summary points In Northern Ireland Genito-Urinary Medicine (GUM) clinics in 2013 • New diagnoses of uncomplicated chlamydia increased by 1% ; 1,699 diagnoses in 2013 compared with 1,676 in 2012. • New diagnoses of uncomplicated gonorrhoea increased by 19%; 537 in 2013 compared with 451in 2012. • New diagnoses of genital herpes simplex (first episode) increased by 8%; 385 in 2013 compared with 357 in 2012. • New diagnoses of genital warts (first episode) decreased by 9%; 1, 989 in 2013 compared with 2190 in 2012. • New diagnoses of infectious syphilis increased by 3%; 72 in 2013 compared with �70 in 2012. �

Gastrointestinal Infections Annual Surveillance Report 2013

The Public Health Agency (PHA)�has a lead role in protecting the population from infection and environmental hazards through a range of core functions including communicable disease surveillance and monitoring, operational support & advice, and education, training and research.�The effective management of infectious disease depends on high quality surveillance. �Surveillance of communicable gastrointestinal infectious disease provides timely information so that public health action can result.�

HIV surveillance in Northern Ireland 2014

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2013.

Epidemiology of tuberculosis in Northern Ireland: Annual surveillance report 2013

This report presents the epidemiological data for tuberculosis cases reported in Northern Ireland.

Surveillance of Influenza in Northern Ireland 2014-2015

The 2014/15 influenza season was characterised by moderate levels of influenza activity.� Primary care consultation rates were higher than in 2013/14 for the majority of the season, although still low overall.� Activity seen in other surveillance was also higher than in 2013/14 year, and showed that the severity and impact of influenza was greater in 2014/15 and affected older age groups most frequently, with more reported respiratory outbreaks, patients with confirmed influenza admitted to Intensive Care Units/High Dependency Units and excess mortality in those over 65 years of a

C. difficile surveillance quarterly report: April-June 2015

C. difficile surveillance quarterly report: April-June 2015��

S. aureus surveillance quarterly report: April-June 2015

S. aureus surveillance quarterly report: April-June 2015

Gastrointestinal Infections Annual Surveillance Report 2014

The Public Health Agency (PHA)�has a lead role in protecting the population from infection and environmental hazards through a range of core functions including communicable disease surveillance and monitoring, operational support & advice, and education, training and research.�

HIV surveillance in Northern Ireland 2015

This report aims to provide an overview of HIV epidemiology in Northern Ireland by collating and analysing information from a number of sources. Although it reflects epidemiological trends over time, its main focus will be on data collected in 2014.

C. difficle surveillance quarterly report: July-September 2015

This quarterly report provides epidemiological data on�C. difficile�in Northern Ireland, and includes key points, a comprehensive�overview of all�C. diff�infections, rates, trends, age-specific information�and statistical process control charts.

S. aureus surveillance quarterly report: July-September 2015

S. aureus surveillance quarterly report: July-September 2015

'Bio-nano interactions: new tools, insights and impacts': summary of the Royal Society discussion meeting

Bio-nano interactions can be defined as the study of interactions between nanoscale entities and biological systems such as, but not limited to, peptides, proteins, lipids, DNA and other biomolecules, cells and cellular receptors and organisms including humans. Studying bio-nano interactions is particularly useful for understanding engineered materials that have at least one dimension in the nanoscale. Such materials may consist of discrete particles or nanostructured surfaces. Much of biology functions at the nanoscale; therefore, our ability to manipulate materials such that they are taken up at the nanoscale, and engage biological machinery in a designed and purposeful manner, opens new vistas for more efficient diagnostics, therapeutics (treatments) and tissue regeneration, so-called nanomedicine. Additionally, this ability of nanomaterials to interact with and be taken up by cells allows nanomaterials to be used as probes and tools to advance our understanding of cellular functioning. Yet, as a new technology, assessment of the safety of nanomaterials, and the applicability of existing regulatory frameworks for nanomaterials must be investigated in parallel with development of novel applications. The Royal Society meeting 'Bio-nano interactions: new tools, insights and impacts' provided an important platform for open dialogue on the current state of knowledge on these issues, bringing together scientists, industry, regulatory and legal experts to concretize existing discourse in science law and policy. This paper summarizes these discussions and the insights that emerged.